Because of the scarcity of randomized trials comparing toxicity and outcomes of intensitymodulated radiotherapy (IMRT) for oropharyngeal cancer (OPC) with 3D-conformal radiotherapy (3DCRT), we performed a matched-pair analysis from prospectively collected data from the Head and Neck Tumor Registry of our institution. In the absence of phase III trials, we believe this approach provides the highest quality data possible. Ninety-two patients treated with 3DCRT were matched (1:1) to 92 patients treated with IMRT for 9 potential predictive factors for toxicity and outcome: gender, age, T-stage, N-stage, tumor subsite, unilateral neck irradiation, chemotherapy, neck dissection and boost technique. Groups were compared for acute and late toxicity, locoregional control (LRC), disease-free survival (DFS), and overall survival (OS). Oncologic outcomes were estimated using Kaplan-Meier analyses and toxicity was analyzed according to Common Terminology Criteria for Adverse Events v3.0. The overall incidence of grade 3 acute toxicity was significantly reduced by IMRT, compared to 3DCRT (45% vs. 70%, p 5 0.001). The need for tube feeding was reduced from 50% to 37% (p 5 0.04). The 3-year actuarial incidence of grade 2 late toxicity was also significantly reduced by IMRT, compared to 3DCRT (20% vs. 45%, respectively; p , 0.0001). The incidence of grade 2 late dysphagia and xerostomia for IMRT vs. 3DCRT were 10% vs. 31% for dysphagia, p 5 0.004 and 13% vs. 37%, for xerostomia, respectively (p 5 0.001). The 3-year Kaplan-Meier estimates of LRC, DFS, and OS for IMRT vs. 3DCRT were 90% vs. 82% (p 5 0.1), 82% vs. 76% (p 5 0.3), and 72% vs. 64% (p 5 0.2), respectively. In conclusion, the presented nonrandomized comparative study of well-matched groups demonstrates the superiority of IMRT vs. 3DCRT for OPC by significantly reducing radiation-induced toxicity without jeopardizing outcomes. The improved therapeutic ratio achieved by the use of IMRT would allow dose escalation of radiotherapy to further improve outcomes of patients with OPC.
Introduction
Over the last few decades, (chemo)radiotherapy has improved locoregional control (LRC) and survival of patients with oropharyngeal cancer (OPC). However, these improvements were achieved at the cost of important toxic effects (1). Intensity-modulated radiotherapy (IMRT) was developed in the late 1990s as an organ-sparing radiation technique and by the early part of the subsequent decade its use has spread rapidly to most radiotherapy departments worldwide for a wide range of indications despite an incomplete understanding of its (dis)advantages, the challenges of IMRT planning, delivery, and quality assurance and the substantially increased cost compared with non-IMRT techniques. Before the wide implementation of IMRT, no single randomized trial has been conducted comparing toxicity of 3-dimensional conformal radiotherapy (3DCRT) with IMRT in patients with head and neck cancer (HNC) . Comparative studies between well-matched groups were seldom performed. Most of the published studies on outcome and toxicity of IMRT for HNC were observational, with or without comparison with historical results. Although most of these studies showed promising results with regard to the reduced toxicity without jeopardizing outcome (2) (3) (4) , others reported that IMRT resulted in LRC-rates that are comparable to those achieved with 3DCRT with a similar risk of severe complications (5).
In view of the lack of prospective randomized data and the ethical dilemmas in devising such a clinical trial, we performed a matched-pair analysis to compare these two radiation techniques with regard to toxicity and oncologic outcomes in patients with OPC treated in our institution. Matched-pair analysis is an appealing method to reduce bias in observational studies by creating two comparable groups with similar baseline factors, thus reducing confounding (6).
Materials and Methods
From January 2000 to June 2011, 432 consecutive patients with OPC were treated with curative intention by (chemo) radiotherapy have been entered into the Head and Neck Tumor Registry of the Erasmus Medical Center-Daniel den Hoed Cancer Center. All patients entered into the database underwent comprehensive head and neck examinations including direct laryngoscopy, a chest X-ray, ultrasound with FNA, head-and-neck MRI or CT scan, and in most cases also PET-scan. All patients were presented in the weekly multidisciplinary head and neck tumor conference, where recommendations were made regarding treatment selection.
Because of the scarcity of phase III trials comparing outcome and toxicity of two commonly used radiation techniques in the treatment of OPC, the standard technique (3DCRT) and the new technique (IMRT), we used the prospectively collected data at our institution to establish a matched-pair analysis. Data from 92 patients treated by means of 3DCRT were matched (1:1) to 92 patients treated by means of IMRT for 9 potential predictive factors for toxicity and oncologic outcome: gender, age (,65 vs. 65 years), T-stage, N-stage, tumor subsite (tonsil and soft palate vs. base of tongue), unilateral nodal irradiation, chemotherapy, neck dissection (ND), and boost technique (brachytherapy vs. external-beam radiotherapy) (Table I) . Stata ® (StataCorp. 2011, release 12) software was used to select a coarsened exact matched pseudo random cohort of patients. The dataset used in the matching process had encrypted unique patient identifiers and outcomes variables were removed, to ensure that the matching was done in a blinded fashion.
Radiotherapy
Patients were immobilized in supine treatment position in a custom-made head-and-neck mask. CT-scan simulation was performed in all patients. Clinical target volume (CTV) and all critical organs in the region of the tumor (the salivary glands, oral cavity, swallowing muscles, cochlea, larynx, spinal cord, and brain stem) were delineated. For external beam irradiation, the CTV was created by adding 10 mm margin to the delineated gross tumor volume (GTV) defined by clinical examination and by the diagnostic MRI, PET-CT scan or at least contrast-enhanced CT scan of the head and neck region. The planning target volume (PTV) included a margin of 5 mm beyond the CTV to account for different targeting uncertainties. In case of brachytherapy boost, the CTV of the primary tumor was implanted with 2 to 3 afterloading catheters, preferably 0.5-1 cm apart. The dose was prescribed to 0.5-0.75 cm of the catheters plane and optimized using dose point optimization. The radiation treatment of both groups consists of first series of 46 Gy (23 fractions, 2 Gy/fraction, 6 fractions/week) to the primary tumor and the neck, either unilaterally in well-lateralized OPC (tumors confined to the tonsillar fossa, the soft palate with at least 1 cm from the midline or the lateral pharyngeal wall) or bilaterally in other cases. With regard to nodal status, patients with N3 or N2c disease were always treated bilaterally, regardless of the primary tumor extension.
In case of T1-2N0, a boost by means of brachytherapy was given to the primary tumor (22 Gy of Pulsed-Dose-Rate) and in case of node-positive OPC, ND was performed at the same session of the brachytherapy just before implantation of the primary tumor for the boost. In patients with T3-4 tumor, a boost of 24 Gy by means of 3DCRT or IMRT (12 fractions, 2 Gy/fraction, 6 fractions/week) was given to the primary tumor alone in case of N0 and to the primary tumor and the involved neck in case of node-positive disease. For patients treated by means of the standard 3DCRT, a set-up verification procedure using orthogonal portal imaging was applied.
Since the introduction of IMRT, the set-up verification was done by using cone-beam CT scan.
When chemotherapy was indicated in case of locallyadvanced disease (T3 or T4 and/or N3), two cycles of cispla-advanced disease (T3 or T4 and/or N3), two cycles of cisplatin were given (100 mg/m 2 on day 1 and 22 of radiotherapy). Creatinine clearance was checked before each administration. Application of chemotherapy was delayed or discontinued in case of neutropenia (count ,1,000/nL) or thrombocytopenia (count ,100/nL) to prevent radiotherapy breaks.
Endpoints
Endpoints of the study were rates of acute and late toxicities, loco-regional control (LRC), disease-free survival (DFS), overall survival (OS).
Acute toxicity (90 days after treatment) was evaluated by the radiation oncologist during the weekly visit of patients to our outpatient's department. Late toxicity (.90 days after treatment) scores were prospectively collected using Common Terminology Criteria for Adverse Events v3.0 (CTCAE). The maximal toxicity scores are reported.
Regarding local and regional failure, the first time recurrence was reported, was used as the moment at which failure was registered. DFS was measured from the date of completion of treatment to the date of first relapse (local, regional or distant) or death.
Follow-up
The treatment response was evaluated by clinical examination 6-8 weeks after completion of treatment and by MRI or CT-scan 12 weeks after treatment. A positron emission tomography (PET) scan was performed if there is any suspicion about the loco-regional response to the (chemo)radiotherapy. Following completion of treatment, patients were followed up 2-monthly for the first year, 3-monthly for the second and third year and 6-monthly thereafter. At each visit, history and clinical examination were performed, including flexible nasoendoscopy.
Statistical Analysis
The incidences of toxicities of both radiation techniques were compared using logistic regression analysis. Survival rates were calculated from the completion of treatment using the Kaplan-Meier technique. The Mann-Whitney sign test was used for non-parametric significance tests. A two-sided p-values , 0.05 were considered statistically significant. All analyses were conduced using Stata ® (v12, StataCorp LP, College Station, Texas, USA).
Results
Patients' demographics of both treatment groups are shown in Table I . Despite the non-randomized nature the study, the groups were very well balanced with regard to the predefined prognostic factors. The median follow-up time was the only significant difference between both groups, since IMRT was introduced later on. Since April 2004, all patients were treated with IMRT. The median follow-up for the 3DCRT and IMRT groups were 68 vs. 36 months (p , 0.0001).
Dose-Volume Analysis
As shown in Table II , excellent target coverage was achieved by both techniques. With regard to normal tissue doses, there was significant sparing of several critical structures without compromising tumor target coverage. Significant reduction of radiation dose was achieved by using IMRT compared to 3DCRT at different organs at risk; ranging from 4% to 42%. Especially contralateral organs at risk, such as salivary glands and cochlea benefited most from the implementation of IMRT.
Acute Toxicity
During treatment patients were evaluated weekly by the radiation oncologist, who advised patients on their dietary intake, initiated tube feeding (when indicated) in consultation with the dietician, initiated analgesics, and monitored patients for acute toxicity.
Both the incidence and severity of acute radiation-induced toxicity was reduced by the introduction of IMRT. The incidence of grade 2 acute toxicity was significantly reduced by the use of IMRT, compared to 3DCRT (62% vs. 88%, p 5 0.001). The same was true for the incidence of grade 3 acute toxicity (45% vs. 70%, p 5 0.001). The most commonly reported severe acute toxicities were mucosal (confluent mucositis), dysphagia (feeding tube dependency) and pain. All these complications were significantly reduced by IMRT (Table III) .
Grade 3 Dysphagia (Feeding Tube Dependency)
Of the entire group, 81 patients (44%) were feeding tube dependent at the end of treatment. However the incidence was lowered over time by using IMRT, compared to 3DCRT (37% vs. 50%, p 5 0.04). The median duration of feeding tube dependency was shorter for IMRT (6 vs. 13 weeks, p 5 0.01). The weaning from the tube feeding over time was also faster in patients treated by IMRT compared to 3DCRT, with 12 (13%), 4 (4%), and 2 (2%) of 92 patients treated by IMRT still had tube feeding 6, 12, and 24 months after treatment, respectively vs. of 22 (24%), 10 (11%) and 8 (9%) of 92 patients treated by 3DCRT, respectively (Figure 1 ).
Late Toxicity
The 3-year actuarial incidence of late toxicity was significantly reduced by IMRT, compared to 3DCRT (20% vs. 45% for grade 2 toxicity, respectively; p , 0.0001 and 6% vs. 17%, for grade 3 toxicity, respectively; p 5 0.02). Xerostomia and dysphagia were the most commonly reported late toxicity (Table III) . The incidence of grade 2 late xerostomia were 13% vs. 37% for IMRT vs. 3DCRT, respectively (p 5 0.001). The corresponding figures for grade 2 late dysphagia were 10% vs. 31%, respectively; p 5 0.004. No grade 4 toxicity was reported in patients treated with IMRT, while 4 patients (4.3%) treated by means of 3DCRT developed grade 4 late toxicity. These patients had troublesome xerostomia, dysphagia necessitating dilatation and painful mucosal ulceration requiring treatment with opiate analgesics and hyperbaric oxygen therapy.
Outcomes
In the entire group, 75 events were reported: 30 in the IMRT and 45 in the 3DCRT group. The crude number of LRF reported in the IMRT vs. 3DCRT groups were 10 (11%) vs. 19 (21%), respectively, (p 5 0.07). The figures for distant failures were 5 (5%) vs. 9 (10%) (p 5 0.2), respectively.
The 3-year Kaplan-Meier rates of LRC, DFS, and OS for IMRT vs. 3DCRT were 90% vs. 82% (p 5 0.1), 82% vs. 76% (p 5 0.3), and 72% vs. 64% (p 5 0.2), respectively (Figures 2A-C) .
Discussion
IMRT has emerged as a powerful new radiation technique within the past two decades to reduce radiation-induced toxicity. The crucial question is whether this sparing of normal tissue effects can be achieved without compromising loco-regional tumor control probability. Given the complex anatomical relations of HNC to different vital structures, standard 3DCRT has been progressively replaced by IMRT in the management of cancers in this region.
Because of the scarcity of phase III trials comparing toxicity and outcomes of both techniques, we used the prospectively collected data at our institution to perform this matched-pair analysis. In the absence of phase III trials, we believe this approach provides the highest quality data possible. In the present study, we compared well matched groups of patients treated by both techniques and found significant reduction in acute and late toxicity and slightly better, or at least comparable, oncologic outcomes by the use of IMRT, compared to 3DCRT. The dose conformality afforded by the use of IMRT does seem to have a substantial effect on the dose received by the adjacent organs at risk, especially salivary glands and swallowing muscles. These dosimetric advantages of IMRT would explain the reduced acute and late toxicity in patients treated with IMRT, as opposed to those treated with 3DCRT. As illustrated in Table II , significant reduction of radiation dose was achieved by using IMRT compared to 3DCRT, ranging from 4% to 42%. Especially contralateral organs at risk, such as salivary glands and cochlea benefited most from the use of IMRT.
Regarding acute toxicity, IMRT reduced the incidence of grade 3 toxicity, compared to 3DCRT (Table III) . The reduction of the incidence and severity of acute toxicity achieved by IMRT seems to be very important, since 80% of patients with grade 3 late toxicity had also grade 3 acute toxicity while only 25% of patients with grade 2 late toxicity had also grade 2 acute toxicity, suggesting a consequential late reaction, especially for the serious grade 3 radiation-induced toxicity. The introduction of IMRT reduced the incidence of feeding tube dependency, shortened the median duration of tube feeding and made phasing out of the tube feeding faster, compared with 3DCRT.
Regarding late toxicity, the incidence of both grade 2 and grade 3 toxicities were also significantly reduced over time by using IMRT. Xerostomia and dysphagia are still the main cause of late radiation-induced morbidity and deterioration of QoL. In the present study, the incidence of grade 2 late xerostomia for IMRT vs. 3DCRT were 13% vs. 37%, respectively; p 5 0.001. The benefit of parotid-sparing IMRT was demonstrated in several small phase II studies (3, 4, 7). Only one randomized controlled trial (PARSPORT-trial) has been published comparing the toxicity and outcome of IMRT with 3DCRT. At 24 months, grade 2 xerostomia was significantly reduced using parotid-sparing IMRT, compared to 3DCRT (29% vs. 83%, p , 0·0001) with clinically significant improvements in QLQ-H&N 35 dry mouth but without significant differences in outcome and non-xerostomia late toxicities (8). Further reduction in the incidence and severity of xerostomia may be achieved by reducing the dose to oral cavity, in addition to sparing of the parotid and the submandibular glands. According to the recently published data from the Michigan group, both patient-reported and observer-rated xerostomia were lowered at almost all posttherapy points when the mean dose in oral cavity was kept below 50 Gy (9).
Much has been achieved with regard to the reduction of xerostomia, whereas no comparable advances have been made to reduce the incidence of dysphagia. The introduction of IMRT at our institution reduced the incidence and the severity of late dysphagia, compared to 3DCRT. In the present study, the incidence of grade 2 late dysphagia for IMRT vs. 3DCRT were 10% vs. 31%, respectively; p 5 0.004. The figures for grade 3 dysphagia were 2% vs. 9%, respectively; p 5 0.001. These results appear in keeping with the published literature  (2, 3, 8 ). Since the introduction of IMRT in our institution, strategies using the possibilities of IMRT to keep the mean radiation dose to constrictor muscles ,50 Gy were implemented in the last six years to reduce late dysphagia. Levendag and colleagues from our group (10) reported a sharp increase in the risk of late dysphagia of approximately 19% per 10 Gy, beyond a mean dose of 55 Gy in superior and middle constrictor muscles. Another explanation of the lower incidence of swallowing problems in our study population might be the policy in our center that we tend not to install PEG up-front. We hypothesize that encouraging patients to use their swallowing mechanisms during treatment for the longest period of time might decrease those patients' likelihood of developing a feeding tube dependency. Furthermore, the lower incidence of dysphagia in the IMRT group might also be partly attributed to the reduced incidence of xerostomia in these patients as dysphagia-related complaints have been shown to increase significantly in patients with reduced production of saliva after chemo(radiation) (11). Teguh et al. (12) reported also on the significant correlation between dysphagia, xerostomia and sticky saliva as important scales of the EORTC H&N 35 questionnaires. Another way to prevent or reduce the severity of dysphagia is by developing and implementing predictive models to identify patients at high risk of developing swallowing dysfunction after curative chemo(radiation) for HNC. These patients might benefit from strategies aiming at preventing or reducing swallowing problems such as swallowing exercises during treatment and the emerging IMRT techniques to reduce the dose to the swallowing apparatus.
A number of recent studies (3, 13, 14) have suggested that not only toxicity but also oncologic outcomes for OPC treated with IMRT compare favourably to 3DCRT. The same trend was also observed at the present study. However, the differences in LRC-rates between both groups were statistically not significant (90% for IMRT vs. 82% for 3DCRT, p 5 0.1). Two possible explanations for improved oncologic outcomes in patients treated by means of IMRT, compared to 3DCRT. The nowadays available promising imaging techniques as dynamic contrast-enhanced MRI and FDG-PET scan might have improved the target identification and localization and subsequently improved LRC by decreasing the chance of geographical missers. Furthermore, the incidence of HPV-positive HNC in Western countries is clearly rising significantly. In the last 5 decades, the incidence of HPV-positive HNC is doubled in every decade. Different studies showed a superior LRC, DFS, and OS rates in HPV-positive OPC, compared to those with HPV-negative tumors (15). However, these conclusions should be interpreted with caution, since we did not collect HPV data on patients in this series. The improved therapeutic ratio achieved by the use of IMRT would allow dose escalation of radiotherapy to further improve outcomes in patients with OPC, especially non-HPV related OPC.
Despite several advantages of this blindly-conducted matched-pair analysis of well-balanced groups, our study is not devoid of limitations. A potential major limitation of this comparison is the differences in follow-up time between both groups. This difference in the follow-up might influence late toxicity and long-term oncologic outcomes. However, 55% of the IMRT group has a follow-up time longer than 2 years. Second, comparing outcomes between groups treated in different periods is a critical concern. However, our treatment protocol has not really changed during the accrual period. Third, despite the fact that the nine potential prognostic factors were very well balanced between both treatment groups (Table I) , hidden selection biases cannot be excluded from the present study.
Conclusions
When no randomized trials have directly compared toxicity and outcome of IMRT before its wide introduction for HNC with the standard 3DCRT, a blindly performed matched-pair analysis provides, in our opinion, the highest quality data possible. The current study showed a significant reduction in acute and late toxicities and slightly better, or at least comparable, oncologic outcomes by the use of IMRT for OPC, compared to 3DCRT.
The highly conformal dose distribution afforded by the use of IMRT resulted in a significant reduction of radiation dose received by the adjacent organs at risk (ranging from 4% to 42%) and subsequently significant reduction in radiationinduced toxicity. With its irregular, often concave shapes and close proximity to critical normal structures such as the salivary glands and the swallowing muscles, the oropharynx appears to be an ideal site for IMRT. The improved therapeutic ratio achieved by the use of IMRT would allow dose escalation of radiotherapy to further improve outcomes of patients with OPC.
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